Human Metapneumovirus Spreads Rapidly Across the United States
Health officials in the United States are monitoring a significant surge in cases of human metapneumovirus (HMPV), a respiratory pathogen with no specific treatment or cure. Despite the rapid spread, authorities are urging the public to remain calm and avoid panic. The virus is transmitted through coughs or contact with contaminated surfaces, leading to cold-like symptoms including cough, fever, runny nose, and sore throat.
Current Surveillance and Data Trends
Latest data from the Centers for Disease Control and Prevention (CDC) reveals that HMPV accounted for five percent of all respiratory infections during the week ending February 21, marking an increase from 3.8 percent in the previous seven-day period. Wastewater monitoring indicates that the virus has reached 'high' levels across all four regions of the country, with particular hotspots identified in California's Bay Area, New York City, and Chicago.
This surge occurs as infections from other respiratory viruses, such as influenza and Covid-19, have remained at lower levels in recent weeks. Dr. Matthew Binnicker, director of clinical virology at the Mayo Clinic, noted in a release: 'In the late winter, early spring, it can account for five to 10 percent of all the respiratory infections that we diagnose in the US. So, it's definitely out there.'
Symptoms, Risks, and Treatment Options
HMPV typically causes a mild illness that resolves within a few days without medical intervention. However, in rare cases, it can lead to serious infections, especially among high-risk groups. Children, teenagers, adults over 65, and individuals with underlying health conditions are considered more vulnerable. Research indicates that 51 percent of high-risk adults infected with HMPV require hospitalization, with a mortality rate of 6.6 percent, though overall deaths from the virus are uncommon.
Patients usually develop symptoms within three to six days of infection. Common signs include coughing, nasal congestion, sore throat, and a slight fever. For treatment, doctors recommend bed rest and increased fluid intake. In severe cases, supportive care such as oxygen therapy may be necessary.
Historical Context and Seasonal Patterns
This marks at least the second surge in HMPV infections since the pandemic, following a similar uptick in 2023. Historical data shows that the virus typically peaks in March or April, with last year's peak occurring in April at a 7.4 percent positivity rate. The highest recorded percentage since the pandemic was in March 2023, reaching 11 percent positivity. Experts anticipate that infections will not begin to decline until June.
Many cases likely go unreported, as individuals with mild symptoms may not seek testing or treatment, suggesting that official figures underestimate the true prevalence. Dr. Monica Gandhi, an infectious disease specialist at UC San Francisco, explained to SFGate that respiratory viruses often 'compete with each other' each season. She added: 'When we had big Covid surges, we saw really low rates of other common cold viruses. Other viruses like influenza and HMPV are now getting their chance.'
Prevention and Comparative Symptoms
The CDC advises regular handwashing, avoiding close contact with sick individuals, and frequent cleaning of surfaces to reduce infection risk. While clinical testing is the most accurate method for diagnosing HMPV, doctors note that symptoms can help differentiate it from other viruses like influenza. For HMPV, symptoms are generally confined to the upper airways, whereas flu often involves more systemic effects such as chills, fever, headaches, muscle aches, and gastrointestinal issues like vomiting and diarrhea.
Dr. Ron Eccles, an infectious diseases expert in the UK, previously told Daily Mail: 'Flu typically causes chills, a fever, headaches, muscle aches and pains. The flu feels worse because the symptoms affect the whole body and are not restricted to the upper airways.'
First detected in 2001, HMPV cases tend to rise during winter months alongside other respiratory diseases. Officials continue to emphasize vigilance and preventive measures while reassuring the public that, for most individuals, the virus remains a mild, self-limiting illness.
